Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
adderall
adverse drug reaction
amphetamines
antidepressant
atomoxetine
attention deficit disorder with hyperactivity
attention deficit disorder with hyperactivity, adult
attention span
behavior modification
complications
concentration, impaired
concerta
conversion reaction
depression
diagnostic criteria
disability, neurological
dizziness
drug induced neurologic disorders
efficacy
episodic disorders
gait disorder
hyperactivity
iatrogenic neurologic disorders
imbalance
imbalance, postural
inattention
movement disorder, psychogenic
neurologic disease, diagnoses of
Parkinson disease
paroxetine
pathologic reflex
patient information and support
Persistent postural-perceptual dizziness
precipitating factors
prognosis
review article
ritalin
safety
selective norepinephrine reuptake inhibitor
selective serotonin reuptake inhibitors
serotonin norepinephrine reuptake inhibitors
serotonin syndrome
stimulant drugs
treatment of neurologic disorder
triptans
venlafaxine
Showing articles 400 to 450 of 891 << Previous Next >>

Personalized Approaches to Clopidogrel Therapy: Are We There Yet?
Stroke 41:2997-3002, Anderson,C.D.,et al, 2010

Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis
Arch Neurol 67:1391-1394, Schr�der,A.,et al, 2010

What if the sexual headache is not a joke?
BJMP 3:304-308, Redelman, M., 2010

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009

Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009

A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009

Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009

Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009

Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009

Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009

Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009

Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009

Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009

Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009

Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009

Donepezil Treatment of Patients with MCI: A 48-Week Randomized, Placebo-Controlled Trial
Neurol 72:1555-1561, Doody,R.S.,et al, 2009

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009

Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009

Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009

Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009

Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009

Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009

Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009

Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009

Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009

Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009

A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008

Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease
Stroke 39:497-502, Vergouwen,M.D.I.,et al, 2008

Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stoke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)
Stroke 39:89-99, Adams,H.P.,Jr.,et al, 2008

SLC01B1 Variants and Statin-Induced Myopathy -- A Genomewide Study
NEJM 359:789-799, The SEARCH Collaborative Group, 2008

Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008

Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008

Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008

Statin Therapy for Stroke Prevention
Stroke 39:1042-1048, Nassief,A. &Marsh,J.D., 2008

Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008

Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008

A Randomized Placebo-Controlled Trial of Ginkgo Biloba for the Prevention of Cognitive Decline
Neurol 70:1807-1817,1730, Dodge,H.H.,et al, 2008

Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study
Neurol 70:2364-2370,2355, Goldstein,L.B.,et al, 2008

Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008

Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1: A Randomized Controlled Trial
JAMA 300:287-294, Krab,L.C.,et al., 2008

Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008

Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008

A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
NEJM 359:1225-1237, Yusuf,S.,et al, 2008



Showing articles 400 to 450 of 891 << Previous Next >>